NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $165K rose 16400.0% year over year, ahead of the +6000.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 65.0% from the prior quarter. Over 3 fiscal years it compounded at +229.4% a year.
Context
- Depreciation & amortization amounted to 11.7% of revenue in FY2025.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +16400.0% holds above the trailing-twelve-month pace of +6000.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 143K USD
- Year-over-year change
- +2760.0%
- 4-year CAGR
- +190.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 143K | +2760.0% |
| FY2024 | 2024-12-31 | 5K | +0.0% |
| FY2023 | 2023-12-31 | 5K | +25.0% |
| FY2022 | 2022-12-31 | 4K | +100.0% |
| FY2021 | 2021-12-31 | 2K | — |
Depreciation & Amortization vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 depreciation & amortization of $305K is the 6th largest of the 9 companies compared; the peer median is $1.89M.
- Its year-over-year change of +6000.0% is the highest of 9, against a peer median of +8.0%.
- Depreciation & amortization amounts to 13.3% of revenue for NRXP, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Jun 2026 | $3.65M | +111.3% | +14.0% | 17.4% | |
| LTM Mar 2026 | $2.9M | +21.7% | -19.1% | 8.9% | |
| LTM Mar 2026 | $2.56M | -49.9% | — | 1.7% | |
| LTM Mar 2026 | $1.23M | +12.3% | +6.9% | 86.8% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| Peer median (excluding NRXP) | $1.89M | +8.0% | -0.6% | 17.4% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.79M | 3.63M | 387K | 486K | 228K |
| Change in Working Capital | (4.9M) | 699K | 5.16M | 5.29M | 1.41M |
| Accounts Receivables | 831K | 0 | 0 | 0 | 48K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (19K) | (1.61M) | 2.66M | (5.22M) | 113K |
| Other Working Capital | (5.71M) | 2.31M | 2.51M | 10.51M | 1.25M |
| Other Non-Cash Items | 52.47M | (4.33M) | 2.94M | 8.71M | 12.73M |
| Operating Cash Flow | (37.7M) | (39.76M) | (21.66M) | (10.64M) | (14.11M) |
| Capital Expenditures | (7K) | (10K) | (3K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (2.38M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (432K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7K) | (10K) | (3K) | 0 | (2.81M) |
| Debt Repayment | (1.28M) | 9.5M | (3.09M) | (1.5M) | 7.42M |
| Common Stock Issued | 36.98M | 22.7M | 8.12M | 5.91M | 15.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.75M | 10K | 0 | 3.07M | 0 |
| Financing Cash Flow | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.75M | (7.55M) | (15.46M) | (3.15M) | 6.35M |
| Free Cash Flow | (37.71M) | (39.77M) | (21.66M) | (10.64M) | (14.11M) |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.